showed that oral supplementation with AKK in nonresponders restored the efficacy of PD-1 blockade in an IL-12-dependent manner by increasing the recruitment of CCR9+, CXCR3+, and CD4+ T lymphocytes to tumor beds in mice (27). This evidence concerns the gene CD4 and neoplasm.